leisure time -WSS

leisure time

author：knowledge 2025-09-29 00:38:27 - browse：8

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Biden warns of ‘dark winter’ during final presidental debate

leisure time

WSS

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Take antibiotics after sex, CDC recommends for certain risk groups

A new crop of companies is reshaping the health data economy

The haunting brain science of long Covid

The most pressing bird flu mysteries scientists want answered

STAT Report: Patient voices and perspectives

focus

leisure time

Wikipedia

Psychedelics group wrestles with new pharma identity

Why patients can’t get everything they want on drug pricing

Malaria cases in Florida and Texas: Here’s what you need to know

Truvian presents data for its desktop blood

At least 13 dead in Texas as scorching temps continue

A new initiative will help leaders fight the next pandemic

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA approves Moderna’s RSV vaccine, its second licensed product

George Santos makes 1st court appearance after pleading not guilty to 13 counts

'Little Tech' descents on D.C., wanting a say in how AI is regulated

hotspot

UHS says company favors patients whose insurance pays more

FDA approves Moderna’s RSV vaccine, its second licensed product

Stopping antidepressants leads to symptoms for 1 in 6 patients

Congress needs to close a vaccine

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

leisure time

focus

leisure time

hotspot